Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2204]

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

ASCO 2020: Special report provides guidance to oncology practices on resuming cancer care during COVID-19 pandemic

ASCO 2020: Special report provides guidance to oncology practices on resuming cancer care during COVID-19 pandemic

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC

FDA approves brigatinib for ALK-positive metastatic NSCLC

FDA approves brigatinib for ALK-positive metastatic NSCLC

Just a little physical activity pays big dividends to high risk breast cancer patients

Just a little physical activity pays big dividends to high risk breast cancer patients

Clinical trial announced to study impact of severe COVID-19 infection on patients who receive stem cell transplants for blood cancers and disorders

Clinical trial announced to study impact of severe COVID-19 infection on patients who receive stem cell...

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer

New biomarker could flag tumours that are sensitive to common diabetes drug

New biomarker could flag tumours that are sensitive to common diabetes drug

Thousands of lives could be lost to delays in cancer surgery during Covid-19 pandemic

Thousands of lives could be lost to delays in cancer surgery during Covid-19 pandemic

More from ecancer